Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
146 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape. Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 22 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 1 molecules, respectively. Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Retinitis Pigmentosa (Retinitis) - Overview 7 Retinitis Pigmentosa (Retinitis) - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 25 Acucela Inc 25 Allergan Plc 25 Amarantus Bioscience Holdings Inc 26 Amgen Inc 26 Applied Genetic Technologies Corp 27 Asklepios BioPharmaceutical Inc 27 Astellas Pharma Inc 28 Caladrius Biosciences Inc 28 Dompe Farmaceutici SpA 29 GenSight Biologics SA 29 Grupo Ferrer Internacional SA 30 ID Pharma Co Ltd 30 InFlectis BioScience 31 Ionis Pharmaceuticals Inc 31 M's Science Corp 32 Mimetogen Pharmaceuticals Inc 32 Nanovector srl 33 Novartis AG 33 Novelion Therapeutics Inc 34 ProQR Therapeutics NV 34 ReNeuron Group Plc 35 SanBio Inc 35 Sanofi 36 Shire Plc 36 Spark Therapeutics Inc 37 Sun Pharma Advanced Research Company Ltd 38 Retinitis Pigmentosa (Retinitis) - Drug Profiles 39 A-004 - Drug Profile 39 AMRS-001 - Drug Profile 40 Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 49 AP-1 - Drug Profile 50 BNP-RP - Drug Profile 51 cenegermin - Drug Profile 52 CPK-850 - Drug Profile 55 cutamesine - Drug Profile 56 FAB-111 - Drug Profile 58 Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 59 Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 60 Gene Therapy for Ocular Diseases - Drug Profile 61 Gene Therapy for Retinitis Pigmentosa - Drug Profile 62 Gene Therapy for Retinitis Pigmentosa - Drug Profile 63 Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 64 Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 65 Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile 66 Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile 67 Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 68 Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 69 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 70 GS-030 - Drug Profile 72 GT-038 - Drug Profile 75 HORAPDE-6B - Drug Profile 77 HORARLBP-1 - Drug Profile 78 IFB-088 - Drug Profile 79 IONISRHO-2.5Rx - Drug Profile 80 KIRA-6 - Drug Profile 81 KUS-187 - Drug Profile 82 LPDF-003 - Drug Profile 83 myriocin - Drug Profile 84 N-acetyl cysteine amide - Drug Profile 85 NT-501 - Drug Profile 86 OCU-100 - Drug Profile 89 QRX-411 - Drug Profile 90 ReN-003 - Drug Profile 91 RST-001 - Drug Profile 95 SAR-421869 - Drug Profile 97 SB-623 - Drug Profile 99 SHP-630 - Drug Profile 103 Small Molecule for Retinitis Pigmentosa - Drug Profile 104 Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 105 Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile 106 Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 107 STC-1 - Drug Profile 108 Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 109 Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 110 Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 111 Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile 112 Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile 114 voretigene neparvovec - Drug Profile 115 zuretinol acetate - Drug Profile 120 Retinitis Pigmentosa (Retinitis) - Dormant Projects 125 Retinitis Pigmentosa (Retinitis) - Discontinued Products 127 Retinitis Pigmentosa (Retinitis) - Product Development Milestones 128 Featured News & Press Releases 128 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1 2017 Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
